Arctic Bioscience AS
The answer first
Does Arctic Bioscience beat the market?
No, Arctic Bioscience has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 23% of Nordic stocks
- Quality41
- Value49
- Trend23
No. 121 of 195 in healthcare
Max for seven days
Follow Arctic Bioscience with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Arctic Bioscience
Your first answer is free, no account needed.
Do you own Arctic Bioscience, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Arctic Bioscience and a few more. Free, no card.
Super Stock+44.6%In short
- Arctic Bioscience has fallen 21.1% over the past year, including dividends.
- Overall, Arctic Bioscience ranks better than 23% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 91.7%. The price is 91.0% below its peak now.
Who owns Arctic Bioscience? See the major shareholders and their stakes
What do analysts think of Arctic Bioscience?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 23% of Nordic stocks.
No. 121 of 195 in healthcare
Medium An average company: the accounts are neither especially strong nor weak.
No. 145 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.45
- Asset turnoverSales divided by everything the company owns0.16
- Return on equityProfit divided by equity−27.9%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Medium Fair price: about the same as a typical Nordic stock.
No. 53 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity0.5
- P/SPrice divided by sales1.6
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 116 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−6.3%
- 6 months−19.9%
- 9 months−19.7%
- 12 months−21.1%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
About Arctic Bioscience
Arctic Bioscience AS is a company in healthcare, listed on Oslo Børs. The share trades in NOK. It has around 19 employees.
Arctic Bioscience AS, a clinical-stage biotechnology company, engages in developing and commercializing pharmaceutical and nutraceutical ingredients based on bioactive marine compounds in Norway, the United States, Europe, and Asia Pacific. The company is developing HRO350, a novel oral drug which is in phase IIb for the treatment of mild-to-moderate psoriasis; and the HeROPA study, an international phase IIb clinical trial. It also sells nutraceuticals as an intermediary and finished goods products under the ROMEGA brand name. Arctic Bioscience AS was incorporated in 2011 and is headquartered in Ørsta, Norway.


See the full analysis of Arctic Bioscience.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card